SCHEDULE 13G/A: Jennison Associates LLC Divests Entire Stake in Phathom Pharmaceuticals, Reports Zero Beneficial Ownership

Sentiment:

Beneficial Ownership Report 9 June 2025 2:47 PM

📋All filings for Phathom Pharmaceuticals, INC

Jennison Associates LLC has filed an amended Schedule 13G, indicating they no longer hold any beneficial ownership in Phathom Pharmaceuticals Inc. as of May 31, 2025.

Worse than expectedJennison Associates LLC, a significant investment adviser, has reduced its beneficial ownership in Phathom Pharmaceuticals Inc. to 0%, indicating a complete divestment of its previous holdings, which is generally perceived as a negative signal by the market.

Summary

Jennison Associates LLC filed an Amendment No. 3 to Schedule 13G concerning their beneficial ownership of Common Stock in PHATHOM PHARMACEUTICALS INC.
As of May 31, 2025, Jennison Associates LLC reports 0% beneficial ownership of Phathom Pharmaceuticals Inc. common stock.
This includes 0 shares with sole voting power, shared voting power, sole dispositive power, and shared dispositive power.
Jennison Associates LLC is classified as an Investment Adviser (IA).
The filing certifies that the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 3

Explanation: The complete divestment of shares by Jennison Associates LLC, an investment adviser, indicates a negative sentiment or a strategic portfolio reallocation away from Phathom Pharmaceuticals Inc.

Negatives

Jennison Associates LLC, a significant investment adviser, has reduced its beneficial ownership in Phathom Pharmaceuticals Inc. to 0%, indicating a complete divestment of its previous holdings.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding Phathom Pharmaceuticals Inc.'s future performance or Jennison Associates LLC's future investment plans.

Management Comments

Jennison Associates LLC certifies that the securities referred to were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Phathom Pharmaceuticals Inc.

Industry Context

This filing reflects a change in institutional investment within the pharmaceutical sector. A complete divestment by an investment adviser like Jennison Associates could signal a re-evaluation of the company's prospects or a broader portfolio reallocation within the healthcare/pharmaceutical industry by the reporting entity.

Stakeholder Impact

Shareholders: May react negatively to the news of a significant institutional investor divesting its entire stake, potentially leading to downward pressure on the stock price.

Key Dates

Date	Description
05/31/2025	Date of event which requires filing of this statement, indicating Jennison Associates LLC's beneficial ownership became 0%.
06/09/2025	Date of signature for the Schedule 13G filing by Jennison Associates LLC.

Recommendation

sell

Keywords

Jennison Associates LLC, Phathom Pharmaceuticals Inc., Schedule 13G, beneficial ownership, common stock, investment adviser, divestment, institutional holding

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.